0

Characterization of Focal Liver Lesions: Use of Mangafodipir Trisodium (MnDPDP)-enhanced MR Images

Aydin Karabacakoğlu, Yüksel Adigüzel, Serdar Karaköse, Ertuğrul Kayaçetin, Rahime Haykir

Turk J Gastroenterol. 2006 Sep;17(3):164-71.

PMID: 16941248

Abstract:

Background/aims:
We evaluated the characterization and detection of liver lesions using mangafodipir trisodium.
Methods:
A total of 51 patients with liver lesions [13 hepatocellular carcinomas, 18 metastases, 14 hemangiomas, three cholangiocellular carcinomas, two hydatic cysts, and one focal nodular hyperplasia (FNH)] were examined by unenhanced and mangafodipir trisodium-enhanced MRI.
Results:
After administration of mangafodipir trisodium by slow intravenous infusion, mangafodipir trisodium-enhanced MRI was performed at 15-30 min and 24 h. The enhancement appeared in normal liver parenchyma and all of the hepatocellular lesions (HCCs and FNH). The lesions in hepatocellular carcinomas patients showed a non-homogeneous enhancement pattern. Non-hepatocellular lesions (hemangiomas, metastases, CCCs) had no enhancement on mangafodipir trisodium-enhanced MRI examinations. The rim-like enhancement pattern was demonstrated in all patients with cholangiocellular carcinomas, and in 14 metastases and 11 hemangiomas.
Conclusions:
Mangafodipir trisodium-enhanced MRI permits reliable distinction between hepatocellular and non-hepatocellular tumors. Mangafodipir trisodium-enhanced MRI can show more functional and morphologic features of hepatocellular lesions. Some non-hepatocellular lesions which went undetected on unenhanced MRI were visualized after contrast enhancement of the liver. The rim-like enhancement pattern is not specific for metastases. Mangafodipir trisodium-enhanced MRI is safe and well tolerated and may aid in noninvasive diagnosis of liver lesions.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP140678144 Mangafodipir trisodium Mangafodipir trisodium 140678-14-4 Price
qrcode